The latest price target for Dare Bioscience (NASDAQ:DARE) was reported by HC Wainwright & Co. on November 15, 2024. The analyst firm set a price target for $12.00 expecting DARE to rise to within 12 months (a possible 278.55% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for Dare Bioscience (NASDAQ:DARE) was provided by HC Wainwright & Co., and Dare Bioscience reiterated their buy rating.

The last upgrade for Dare Bioscience Inc happened on May 15, 2024 when Brookline Capital raised their price target to $3. Brookline Capital previously had a hold for Dare Bioscience Inc.

The last downgrade for Dare Bioscience Inc happened on August 14, 2024 when Maxim Group changed their price target from N/A to N/A for Dare Bioscience Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Dare Bioscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Dare Bioscience was filed on November 15, 2024 so you should expect the next rating to be made available sometime around November 15, 2025.

While ratings are subjective and will change, the latest Dare Bioscience (DARE) rating was a reiterated with a price target of $12.00 to $12.00. The current price Dare Bioscience (DARE) is trading at is $3.17, which is out of the analyst’s predicted range.